The Latest Cardiac and Vascular News
DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%, or 12% in constant currency, compared to $253 million in […]
The AFX2 System integrates anatomical fixation into aortic endografts with an advanced delivery system to treat patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, announced that is has received […]
CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2022 that were approved by the Compensation Committee of its Board of […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022. Financial Summary and Highlights1 Revenue of $254.2 million for the quarter, decreased 3.9 percent on a reported basis and increased 0.5 percent on a constant-currency basis, as compared […]
Webcast Scheduled for Tomorrow, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET) Revenues of $62.5 million increased 11% sequentially compared to third quarter this year and decreased 12% compared to fourth quarter last year Management provides fiscal 23 revenue guidance of $255 million to $265 million, representing 8% […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of […]
PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended June 30, 2022. Second Quarter 2022 Financial Results Total Q2 […]
2022 Q2 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.8 million, an increase of 4%, compared to $14.3 million Net income was $4.1 million, or $0.60 per basic share and $0.51 per diluted share, compared to $6.7 million, or $1.00 per basic share and $0.83 per diluted share Cash and cash equivalents at June 30, 2022 increased to $40.0 million from $28.5 million SANTA […]
Regeneron’s press release reporting its second quarter 2022 results is also available on its media and investor relations website (http://newsroom.regeneron.com) Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 20% Second quarter 2022 EYLEA® U.S. net sales increased 14% versus second quarter 2021 to a […]
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* […]
